Evidence map›Paper›PMID 34448173›Full record

ArticleRheumatology and therapy2021

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study.

Sei Muraoka, Zento Yamada, Mai Kawazoe, Wataru Hirose, Hajime Kono, Shinsuke Yasuda, Yukiko Komano, Hiroshi Kawano, Toshihiko Hidaka, Shusaku Nakashima and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Sei MuraokaDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.ORCID http://orcid.org/0000-0002-9853-8057
Zento YamadaDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.ORCID http://orcid.org/0000-0001-6958-6706
Mai KawazoeDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Wataru HiroseHirose Clinic of Rheumatology, Saitama, Japan.ORCID http://orcid.org/0000-0001-9095-6951
Hajime KonoDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4578-8677
Shinsuke YasudaDepartment of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID http://orcid.org/0000-0001-6171-2077
Yukiko KomanoDepartment of Rheumatology, Jujo Takeda Rehabilitation Hospital, Kyoto, Japan.ORCID http://orcid.org/0000-0002-2803-8655
Hiroshi KawanoDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.ORCID http://orcid.org/0000-0001-9812-4615
Toshihiko HidakaInstitute of Rheumatology, Zenjinkai Miyazaki-Zenjinkai Hospital, Miyazaki, Japan.
Shusaku NakashimaDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan.ORCID http://orcid.org/0000-0002-9556-1171
Tsuyoshi KasamaDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3871-6456
Tamio TeramotoTeikyo Academic Research Center, Teikyo University School of Medicine, Tokyo, Japan.
Toshihiro NankiDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan. toshihiro.nanki@med.toho-u.ac.jp.ORCID http://orcid.org/0000-0002-3482-074X
ABT-ATS study group
Toho University · JPTeikyo University · JPHirose Electric (Japan) · JPKagawa University · JPShowa University · JPTakeda (Japan) · JPTokushima University · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAbatacept efficacy in older patients with rheumatoid arthritis (RA) has been primarily demonstrated via retrospective comparisons with younger patients. The objective of this study was to compare efficacy of abatacept in older vs. younger patients with RA, and efficacy of abatacept with that of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in both age groups.

methodsThis prospective, multicenter, observational study (UMIN000014913) enrolled csDMARD-refractory patients without previous biological DMARD treatment. Abatacept (A) or csDMARDs (C) were administered at the treating physician's discretion to older (O, ≥ 65 years) and younger (Y, 20-64 years) patients, producing AO, AY, CO, and CY groups. Clinical efficacy after 24 weeks was evaluated using European League Against Rheumatism (EULAR) erythrocyte sedimentation rate response criteria.

resultsOverall, 202 patients were evaluated. Compared with the CO group, more patients in the AO group achieved a EULAR good or moderate response (p < 0.0001). Compared with the CY group, more patients in the AY group achieved a EULAR good or moderate response (p < 0.01). Similar proportions of patients in the AO and AY groups achieved a EULAR good response or a good or moderate response. Few adverse events were reported.

conclusionsThis prospective study demonstrated that abatacept is efficacious and safe in older patients with RA and a history of being refractory to csDMARDs. Abatacept was shown to be more efficacious than adding or switching to a new csDMARD in both younger and older csDMARD-refractory patients with RA.

trial registrationUMIN000014913.

Indexed as

AbataceptAgedAntirheumatic agentsProspective studiesRheumatoid arthritisTreatment outcome

Identifiers

PMID34448173
PMCPMC8572263
OpenAlexW3194468605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.